Product image of Letybo (Botulinum Toxin Type A) supplied by GNH India

Letybo

Active Ingredient:
Botulinum Toxin Type A
Origin:
EU

Letybo (Botulinum Toxin Type A)

Botulinum toxin type A, the active ingredient in Letybo, is a neurotoxin presented as a sterile injectable for intramuscular use. It temporarily reduces muscle activity in several neuromuscular conditions and is administered by a qualified healthcare professional.
GNH India supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Croma Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letybo, a botulinum toxin type A product, acts on overactive muscle activity in several neurological disorders.

  • Cervical dystonia: reduces abnormal neck muscle contractions and associated pain.
  • Blepharospasm: relieves involuntary eyelid closure.
  • Upper‑limb spasticity: improves range of motion and functional use of the arm.
  • Chronic migraine: decreases the frequency of headache days.
  • Axillary hyperhidrosis: reduces excessive sweating in the underarm area.

How It Works

  • Botulinum toxin type A cleaves the SNAP‑25 protein within presynaptic nerve terminals, preventing the vesicular release of acetylcholine at the neuromuscular junction. This inhibition blocks nerve‑muscle transmission, resulting in a localized, reversible paralysis of the injected muscle fibers while preserving sensory function.

Side Effects

Letybo may cause a range of adverse reactions following intramuscular injection.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Bruising: localized discoloration due to minor bleeding.
  • Headache: transient headache after treatment.
  • Localized muscle weakness: temporary reduction in strength of nearby muscles.
  • Flu‑like symptoms: mild fever, fatigue, or malaise.

Serious or Rare Side Effects

  • Dysphagia: difficulty swallowing that may require medical attention.
  • Respiratory compromise: reduced breathing capacity due to spread of toxin.
  • Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals.
  • Systemic botulism‑like symptoms: generalized weakness, vision changes, or drooping eyelids.
  • Vision changes: blurred vision or double vision.

Precautions & Warnings

Before using Letybo, clinicians should consider several safety measures.

  • Neuromuscular disease assessment: evaluate for conditions such as myasthenia gravis.
  • Infection risk: avoid injection into areas with active infection.
  • Anticoagulant use: monitor for increased bruising or bleeding.
  • Spread of toxin: observe for symptoms beyond the injection site.
  • Hypersensitivity: contraindicated in patients with known allergy to botulinum toxin type A.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Letybo can interact with other medications that affect neuromuscular transmission.

Major Interactions (Avoid)

  • Aminoglycoside antibiotics: may potentiate neuromuscular blockade.
  • Quinine: can increase risk of severe muscle weakness.
  • Dantrolene: may enhance the paralytic effect.

Moderate Interactions (Monitor Closely)

  • Anticholinesterase agents: may reduce the efficacy of botulinum toxin.
  • Calcium channel blockers: possible additive muscle relaxation.
  • General anesthetics (e.g., succinylcholine): increased risk of prolonged paralysis.
  • Muscle relaxants: monitor for excessive weakness.
  • Botulinum antitoxin: may neutralize therapeutic effect.

Frequently Asked Questions

Letybo contains botulinum toxin type A and is indicated for the temporary reduction of muscle activity in conditions such as cervical dystonia, blepharospasm, upper‑limb spasticity, chronic migraine, and axillary hyperhidrosis, administered by a qualified healthcare professional.

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction by cleaving the SNAP‑25 protein, preventing nerve‑muscle signaling and causing a reversible, localized paralysis of the targeted muscle fibers.

The dose is individualized by the prescribing clinician based on the specific indication, muscle groups treated, and patient characteristics; dosing guidelines are provided in the product’s prescribing information.

Safety data in pregnant or nursing women are limited; the product should only be used if the potential benefit justifies the potential risk, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Letybo contains the same type A neurotoxin as other branded products, but differences may exist in formulation, vial size, and approved indications. Clinical efficacy and safety are comparable when administered by experienced clinicians, while pricing and supply logistics can vary between manufacturers.

Letybo must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Vials should remain in the original packaging until use, and any unused portion must be discarded according to local regulations.

Letybo is supplied as a sterile injectable solution for intramuscular injection. A qualified healthcare professional reconstitutes the vial with the appropriate diluent, selects injection sites based on the targeted muscles, and injects the calculated dose using aseptic technique.

Serious adverse events include dysphagia, respiratory compromise, generalized muscle weakness, allergic reactions such as anaphylaxis, and systemic spread of toxin leading to botulism‑like symptoms. Prompt medical attention is required if these occur.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any excipients, in patients with infection at the planned injection site, and in those with certain neuromuscular disorders such as myasthenia gravis or Lambert‑Eaton syndrome, unless a specialist determines benefit outweighs risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Botulinum Toxin Type A

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT